Synthesis and crystal structures of new chiral 3-amino-2H-azirines and the Pd complex of one of them

Acta Crystallogr C Struct Chem. 2023 Mar 1;79(Pt 3):104-111. doi: 10.1107/S2053229623001468. Epub 2023 Feb 23.

Abstract

3-Amino-2H-azirines are potentially versatile building blocks in heterocyclic and peptide synthesis. Three new 3-amino-2H-azirines have been synthesized as racemates or mixtures of diastereoisomers in cases where another chiral residue is incorporated as the exocyclic amine. The crystal structures of two of them, an approximately 1:1 diastereoisomeric mixture of (2R)- and (2S)-2-ethyl-3-[(2S)-2-(1-methoxy-1,1-diphenylmethyl)pyrrolidin-1-yl]-2-methyl-2H-azirine, C23H28N2O, 11, and 2-benzyl-3-(N-methyl-N-phenylamino)-2-phenyl-2H-azirine, C22H20N2, 12, and the third as its diastereoisomeric trans-PdCl2 complex, trans-dichlorido[(2R)-2-ethyl-2-methyl-3-(X)-2H-azirine][(2S)-2-ethyl-2-methyl-3-(X)-2H-azirine]palladium(II), where X = N-{[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]methyl}-N-phenylamino, [PdCl2(C21H30N2)2], 14, have been determined and the geometries of the azirine rings compared with those of 11 other 3-amino-2H-azirine structures reported in the literature. Most notable is the very long formal N-C single bond, which is, with one exception, around 1.57 Å. Each compound has crystallized in a chiral space group. The Pd atom in the trans-PdCl2 complex is coordinated by one of each of the pair of diastereoisomers, while both of the diastereoisomers share the same crystallographic site in the structure of 11; this property thereby manifesting itself as disorder. The chosen crystal of 12 is either an inversion twin or composed of a pure enantiomorph, but this could not be established specifically.

Keywords: 3-amino-2H-azirines; Pd–azirine complex; azirine rings; crystal structure; diastereoisomers; organic synthesis.

Grants and funding

Funding for this research was provided by: Alfred Werner Legat (grant to CBB; studentship to CBB); Prof. Dr. Hans E. Schmid-Stiftung (grant to JMV; studentship to JMV); Swiss National Science Foundation (grant to HH); F. Hoffmann–La Roche AG, Basel (grant to HH).